Literature DB >> 15090189

Identification of signal transduction pathways used by orphan g protein-coupled receptors.

Janine N Bresnick1, Heather A Skynner, Kerry L Chapman, Andrew D Jack, Elize Zamiara, Paul Negulescu, Kevin Beaumont, Smita Patel, George McAllister.   

Abstract

The superfamily of GPCRs have diverse biological roles, transducing signals from a range of stimuli, from photon recognition by opsins to neurotransmitter regulation of neuronal function. Of the many identified genes encoding GPCRs, >130 are orphan receptors ( i.e., their endogenous ligands are unknown), and this subset represents putative novel therapeutic targets for pharmaceutical intervention in a variety of diseases. As an initial step toward drug discovery, determining a biological function for these newly identified receptors is of vital importance, and thus identification of a natural ligand(s) is a primary aim. There are several established methods for doing this, but many have drawbacks and usually require some in-depth knowledge about how the receptor functions. The technique described here utilizes a transcription-based reporter assay in live cells. This allows the determination of the signal transduction pathway any given oGPCR uses, without any prior knowledge of the endogenous ligand. This can therefore reduce the redundancy of effort involved in screening ligands at a given receptor in multiple formats (i.e., Galpha(s), Galpha(i/0), and Galpha(q) assays), as well as ensuring that the receptor targeted is capable of signaling if appropriately activated. Such knowledge is often laboriously obtained, and for almost all oGPCRs, this kind of information is not yet available. This technology can also be used to develop inverse agonist as well as agonist sensitive high throughput assays for oGPCRs. The veracity of this approach is demonstrated, using a number of known GPCRs. The likely signaling pathways of the GPR3, GPR12, GPR19, GPR21, and HG55 oGPCRs are shown, and a high throughput assay for GPR26 receptors developed. The methods outlined here for elucidation of the signal transduction pathways for oGPCRs and development of functional assays should speed up the process of identification of ligands for this potentially therapeutically useful group of receptors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15090189     DOI: 10.1089/15406580360545053

Source DB:  PubMed          Journal:  Assay Drug Dev Technol        ISSN: 1540-658X            Impact factor:   1.738


  13 in total

1.  Head bobber: an insertional mutation causes inner ear defects, hyperactive circling, and deafness.

Authors:  Giuseppina Somma; Heather M Alger; Ryan M McGuire; Jim D Kretlow; Fernanda R Ruiz; Svetlana A Yatsenko; Pawel Stankiewicz; Wilbur Harrison; Etai Funk; Antonio Bergamaschi; John S Oghalai; Antonios G Mikos; Paul A Overbeek; Fred A Pereira
Journal:  J Assoc Res Otolaryngol       Date:  2012-03-02

2.  Identification of anti-inflammatory targets for Huntington's disease using a brain slice-based screening assay.

Authors:  Peter H Reinhart; Linda S Kaltenbach; Christian Essrich; Denise E Dunn; Joshua A Eudailey; C Todd DeMarco; Gregory J Turmel; Jennifer C Whaley; Andrew Wood; Seongeun Cho; Donald C Lo
Journal:  Neurobiol Dis       Date:  2011-03-31       Impact factor: 5.996

3.  G protein-coupled receptor 21 deletion improves insulin sensitivity in diet-induced obese mice.

Authors:  Olivia Osborn; Da Young Oh; Joanne McNelis; Manuel Sanchez-Alavez; Saswata Talukdar; Min Lu; Pingping Li; Lucinda Thiede; Hidetaka Morinaga; Jane J Kim; Jan Heinrichsdorff; Sarah Nalbandian; Jachelle M Ofrecio; Miriam Scadeng; Simon Schenk; John Hadcock; Tamas Bartfai; Jerrold M Olefsky
Journal:  J Clin Invest       Date:  2012-06-01       Impact factor: 14.808

Review 4.  GPR3, GPR6, and GPR12 as novel molecular targets: their biological functions and interaction with cannabidiol.

Authors:  Alyssa S Laun; Sarah H Shrader; Kevin J Brown; Zhao-Hui Song
Journal:  Acta Pharmacol Sin       Date:  2018-06-25       Impact factor: 6.150

5.  Metabolic parameters and emotionality are little affected in G-protein coupled receptor 12 (Gpr12) mutant mice.

Authors:  Elisabeth Frank; Yizhen Wu; Naomi Piyaratna; William James Body; Peta Snikeris; Timothy South; Anna-Karin Gerdin; Mikael Bjursell; Mohammad Bohlooly-Y; Leonard Storlien; Xu-Feng Huang
Journal:  PLoS One       Date:  2012-08-07       Impact factor: 3.240

6.  Targeted inactivation of GPR26 leads to hyperphagia and adiposity by activating AMPK in the hypothalamus.

Authors:  Daohong Chen; Xiaolei Liu; Weiping Zhang; Yuguang Shi
Journal:  PLoS One       Date:  2012-07-16       Impact factor: 3.240

7.  Regulation of meiotic prophase arrest in mouse oocytes by GPR3, a constitutive activator of the Gs G protein.

Authors:  Leon Freudzon; Rachael P Norris; Arthur R Hand; Shigeru Tanaka; Yoshinaga Saeki; Teresa L Z Jones; Mark M Rasenick; Catherine H Berlot; Lisa M Mehlmann; Laurinda A Jaffe
Journal:  J Cell Biol       Date:  2005-10-24       Impact factor: 10.539

Review 8.  Intercellular Lipid Mediators and GPCR Drug Discovery.

Authors:  Dong-Soon Im
Journal:  Biomol Ther (Seoul)       Date:  2013-11       Impact factor: 4.634

9.  Regulating the effects of GPR21, a novel target for type 2 diabetes.

Authors:  Siobhán Leonard; Gemma K Kinsella; Elisa Benetti; John B C Findlay
Journal:  Sci Rep       Date:  2016-05-31       Impact factor: 4.379

Review 10.  Advances in Neurobiology and Pharmacology of GPR12.

Authors:  Gonzalo Allende; Jesús Chávez-Reyes; Raquel Guerrero-Alba; Priscila Vázquez-León; Bruno A Marichal-Cancino
Journal:  Front Pharmacol       Date:  2020-05-08       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.